Biopharmaceutics PYQs – Set 21

By Atul Sahu • Biopharmaceutics, Subject Wise PYQs

Biopharmaceutics PYQs – Set 21

Subject : Biopharmaceutics

401. Para aminohippuric acid (PAH) clearance test is used to measure

Biopharmaceutics • ADME • GPAT 2023

A. Renal blood flow B. Liver blood flow C. Cerebral blood flow D. Venous blood flow

402. Following statement is more accurate with respect to limitations of Arrhenius relationship for stability prediction

Biopharmaceutics • Arrhenius relationship limits • GPAT 2023

A. Order of degradation will alter at higher temperature B. Equal moisture concentrations will be mentioned at different temperatures C. Less relative humidity and oxygen solubility at higher temperature D. Same degradation mechanisms may predominate at different temperatures

403. What is true about bioavailability?

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. Amount of unbound drug (free drug reaching systemic circulation) B. Amount of bound drug C. Amount of metabolite drug D. Amount of excreted drug

404. Which method is not suitable to calculate the area under the curve (AUC)?

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. Least square method B. Weighing and platometry C. Trapezoid rule D. Integration of the curve

405. Bioavailability differences among a drug’s oral formulations are most likely to occur if the drug

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. Is freely water soluble B. Is incompletely absorbed C. Is completely absorbed D. Undergoes little first pass metabolism

406. What will be the AUC value of lidocaine if the administered dose is 0.2 g and the total body clearance is 45 L/h?

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. 4.44 h·mg/L B. 0.0044 h·mg/L C. 9.00 h·mg/L D. 9000 h·mg/L

407. Bioavailability of a drug refers to

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. The ratio of drug excreted unchanged in urine to that excreted as metabolites B. The fraction of the drug reaching the target site to produce the action C. The length of time an administered drug is available for action D. The percentage of the administered dose that reaches systemic circulation unchanged

408. A drug of low water solubility when given orally is absorbed up to 90% of the administered dose. The drug belongs to which class according to BCS classification?

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. Class IV B. Class III C. Class II D. Class I

409. Which dosage form of digoxin will provide greater bioavailability based on value of F

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. F equals 1.0 B. F equals 0.32 C. F equals 0.62 D. F equals 0.77

410. IVIVC utilizes the principles of statistical moment analysis, corresponding to which level?

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. Level A B. Level B C. Level C D. Level D

411. The proportion of NaCl liquid to give a 1.5% solution of drug isotonic with blood plasma is:- (Given: Freezing point of 1% w/v drug solution is -0.122 °C and of NaCl is -0.576 °C)

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. 0.0079 B. 0.0059 C. 0.009 D. 0.005

412. Which of the following levels of IVIVC is represented by the relationship between one dissolution time point (e.g., t₅₀%) and one mean pharmacokinetic parameter (e.g., AUC, Tₘₐₓ, or Cₘₐₓ)?

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. Level A B. Level B C. Level C D. Level D

413. Match the following concept in List I with parameters in List II: A. Volume of Distribution B. Evans Blue C. 3.5–5% D : Metallothionin. Choose the correct matching.

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. A–I, B–II, C–III, D–IV B. A–V, B–IV, C–III, D–II C. A–IV, B–I, C–II, D–V D. A–III, B–II, C–IV, D–V

414. Which molecular characteristic enhances aqueous solubility of a solute?

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. A high melting point B. The presence of a polar group C. A high molecular surface area D. A high boiling point

415. Which in-vitro/in-vivo correlation level compares % drug released to % drug absorbed?

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. Level C B. Level A C. Multiple Level C D. Level B

416. Bioavailability studies are ideally carried out in which group of volunteers?

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. Aged individuals B. Children C. Healthy individuals D. Patients

417. Examples of BCS class III drugs are:

Biopharmaceutics • Bioavailability and Bioequivalence • GPAT 2023

A. Taxol, Ellagic acid, Aspirin B. Chloroquine, Diltiazem, Metoprolol C. Acyclovir, Atenolol, Captopril D. Aspirin, Paracetamol, Amoxycillin

418. For drug substances with highly variable pharmacokinetic characteristics the following Bioequivalence study design is used

Biopharmaceutics • Bioequivalence design • GPAT 2023

A. Parallel Design B. Non-Replicate Design C. Non-Parallel Design D. Replicate Design

419. What causes a reduction in dissolution rate by decreasing effective surface area?

Biopharmaceutics • Dissolution & Release Kinetics • GPAT 2023

A. Addition of cyclodextrin B. Increased surfactant surface tension C. Addition of hydrophilic diluent D. Surface charges from extreme size reduction

420. Following are endogenous carriers used for targeted drug delivery except:-

Biopharmaceutics • Drug Delivery and Carriers • GPAT 2023

A. Lipoprotein B. Serum Albumin C. Erythrocyte D. Microparticulates

Disclaimer for MCQ Quiz
The questions in this MCQ quiz are intended solely for educational purposes. While we strive to ensure accuracy, the information may not always be up-to-date or complete. The creators are not liable for any errors or consequences. Verify any information before relying on it for critical decisions.

इस MCQ क्विज़ के प्रश्न केवल शैक्षिक उद्देश्यों के लिए हैं। हम सामग्री की सटीकता सुनिश्चित करने का प्रयास करते हैं, फिर भी जानकारी हमेशा अद्यतित या पूर्ण नहीं हो सकती। निर्माता किसी भी परिणाम के लिए जिम्मेदार नहीं हैं। कृपया किसी भी महत्वपूर्ण निर्णय से पहले स्वतंत्र रूप से जांचें।
https://www.growuppharma.in
यदि कोई गलती है या सुझाव हो तो ईमेल करें: growuppharmacy@gmail.com

Leave a Comment Cancel Reply